---
document_datetime: 2025-09-30 13:18:39
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ozempic-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ozempic-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6849624
conversion_datetime: 2025-12-28 18:18:03.49978
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ozempic

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 25/09/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000287437                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. - - Accepted C.I.z - to update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the Package Leaflet to include the warning for Non- Arteritic Anterior Ischemic Optic Neuropathy (NAION) in line with the outcome of the Pharmacovigilance Risk Assessment Committee (PRAC) Assessment Report for the Post-Authorisation Measure Procedures EMA/PAM/0000262449, EMA/ PAM/0000262475, and EMA/PAM/0000262468 of PSUR EMEA/H/C/PSUSA/00010671/202405 (1   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000279598 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.z Other changes, including change from single batch size to a range of batch sizes - Accepted                                                                                                                                                                                                                                                                                                                                                                      | 28/08/2025 | N/A |
| Variation type IB / EMA/VR/0000275308 | This was an application for a group of variations. B.II.g.5 Implementation of changes foreseen in an approved change management                                                                                                                                                                                                                                                                                                                                                                                                                                       | 04/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | protocol - B.II.g.5.c Implementation of a change for a biological/immunological medicinal product - Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.f The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line) - Accepted                                                                                                                                                                                                                                                                                 |            |     |      |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type II / EMA/VR/0000244910 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.1, and 5.1 of the SmPC in order to update the efficacy information based on final results from study NN9535- 4533 (STRIDE); this is a 52-week, randomised, double-blind, placebo-controlled phase 3b trial evaluating effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease. The study concerns clinical pharmacokinetics, efficacy and safety. | 19/06/2025 |     | SmPC |
| Variation type IB / EMA/VR/0000266216 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/05/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                       | manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type II / EMA/VR/0000249034 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add headache to the list of adverse drug reactions (ADRs) with frequency common following review of the clinical trial and post- marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring editorial changes to the PI. | 22/05/2025 |     | SmPC and PL |
| Variation type IA / EMA/VR/0000267870 | B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted B.II.e.7 Change in supplier of packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 20/05/2025 | N/A |             |

<div style=\"page-break-after: always\"></div>

|                                       | components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted                                                                                                                                                                                                                                                                                                                                        |            |     |                        |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| Variation type IB / EMA/VR/0000263973 | B.II.g.4 Changes to an approved change management protocol - B.II.g.4.b Minor changes to an approved change management protocol that do not change the strategy defined in the protocol - Accepted                                                                                                                                                                                                                                                         | 29/04/2025 | N/A |                        |
| Variation type IB / EMA/VR/0000262655 | This was an application for a group of variations. B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.c Implementation of a change for a biological/immunological medicinal product - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted | 25/04/2025 | N/A |                        |
| Variation type II / EMA/VR/0000256592 | This was an application for a group of variations. B.II.d.1 Change in the specification                                                                                                                                                                                                                                                                                                                                                                    | 10/04/2025 |     | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted B.IV.1 Change of a measuring or administration device - B.IV.1.c Addition or replacement of a device which is an integrated part of the primary packaging - Accepted B.II.e.5 Change in pack size of the finished product - B.II.e.5.c Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/ immunological medicinal products - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.2 After first opening (supported by real time data) - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack -   |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000244317 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | No 1234/2008. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted                     |            |      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type IB / EMA/VR/0000245602 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted | 13/02/2025 | SmPC |